NCT02287428 — NeoVax neoantigen vaccine trial
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
NeoVax personalized neoantigen peptide vaccine, Dana-Farber — with radiotherapy + pembrolizumab in newly diagnosed glioblastoma, Phase 1
Registry record
| Registry ID | NCT02287428 ↗ |
|---|---|
| Lead sponsor | Dana-Farber Cancer Institute |
| Collaborators | The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme LLC, National Institutes of Health (NIH) |
| Phase | Phase 1 |
| Status | Active Not Recruiting |
| Indication | Glioblastoma |
| Enrollment | 56 participants (target) |
| Start date | 2014-11 |
| Primary completion | 2027-02 (est.) |
| Last registry update | 17 Apr 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT02287428), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT02287428?
NCT02287428 (Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM) is registered on ClinicalTrials.gov as Phase 1, sponsored by Dana-Farber Cancer Institute.
Is NCT02287428 recruiting?
As of the 2026-04-17 registry update, NCT02287428 is listed as "Active Not Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT02287428?
The lead sponsor is Dana-Farber Cancer Institute. Collaborators: The Ben & Catherine Ivy Foundation, Accelerate Brain Cancer Cure, Merck Sharp & Dohme LLC, National Institutes of Health (NIH).
What condition does NCT02287428 study?
The registered condition is Glioblastoma. Primary completion is listed as 2027-02 (estimated).
Are results available for NCT02287428?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT02287428.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.